We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Cells Identified for Spinal-Cord Repair Could Lead to Nonsurgical Treatment for Injuries

By LabMedica International staff writers
Posted on 14 Aug 2008
Investigators have located stem cells within the spinal cord that, if persuaded to differentiate into more healing cells and fewer scarring cells following an injury, may lead to a new, nonsurgical treatment for incapacitating spinal-cord injuries. More...


The research, reported in the July 2008, issue of the journal PLoS Biology, was conduced by Dr. Konstantinos Meletis, a postdoctoral fellow at the Massachusetts's Institute of Technology (MIT; Cambridge, MA, USA) Picower Institute, and colleagues at the Karolinska Institute (Stockholm, Sweden). Their findings could lead to drugs that might reestablish some degree of mobility to the 30,000 individuals worldwide afflicted each year with spinal-cord injuries.

In a developing embryo, stem cells differentiate into all the specialized tissues of the body. In adults, stem cells perform similar to a repair system, replenishing specialized cells, but also maintaining the normal turnover of regenerative organs such as skin, blood, or intestinal tissues. The very small numbers of stem cells in the adult spinal cord proliferate slowly or rarely, and fail to promote regeneration on their own. But recent research demonstrates that these same cells, grown in the lab and returned to the injury site, can restore some function in paralyzed rodents and primates.

The researchers at MIT and the Karolinska Institute discovered that neural stem cells in the adult spinal cord are limited to a layer of cube- or column-shaped, cilia-covered cells called ependymal cells. These cells comprise the thin membrane lining the inner-brain ventricles and the connecting central column of the spinal cord. "We have been able to genetically mark this neural stem cell population and then follow their behavior,” Dr. Meletis noted. "We find that these cells proliferate upon spinal cord injury, migrate toward the injury site, and differentiate over several months.”

The study revealed the molecular process underlying the exciting results of the rodent and primate and goes one step further: By identifying for the first time where this subpopulation of cells is found, they have led a way toward modifying them with drugs to enhance their inborn capability to repair damaged nerve cells.

"The ependymal cells' ability to turn into several different cell types upon injury makes them very interesting from an intervention aspect: Imagine if we could regulate the behavior of this stem cell population to repair damaged nerve cells,” Dr. Meletis said.

Upon injury, ependymal cells proliferate and migrate to the injured area, generating a mass of scar-forming cells, plus fewer cells called oligodendrocytes. The oligodendrocytes restore the myelin, or coating, on nerve cells' long, slender, electrical impulse-carrying projections called axons.

"The limited functional recovery typically associated with central nervous system injuries is in part due to the failure of severed axons to regrow and reconnect with their target cells in the peripheral nervous system that extends to our arms, hands, legs, and feet,” Dr. Meletis said. "The function of axons that remain intact after injury in humans is often compromised without insulating sheaths of myelin.”

If scientists could genetically engineer ependymal cells to produce more myelin and less scar tissue after a spinal cord injury, they could potentially avoid or reverse many of the debilitating effects of this type of injury, according to the researchers.

Related Links:
Massachusetts's Institute of Technology
Karolinska Institute

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.